|drug2866||SARS-CoV-2 and/or MIS-C Exposure Wiki||0.71|
|D018352||Coronavirus Infections NIH||0.05|
|D045169||Severe Acute Respiratory Syndrome NIH||0.03|
There are 2 clinical trials
The researchers are doing this study to find out whether the study drug hydroxychloroquine can prevent infection with the COVID-19 virus, compared with placebo, in people who are receiving radiation therapy for their cancer. The placebo used in this study is a tablet that looks the same as the study drug and is taken in the same way, but it does not contain any active ingredients.
Description: Any patients who are enrolled and subsequently test positive for SARS-CoV-2 by RT-PCR (outside RT-PCR test results allowed) at any point during the 9 weeks following enrollment will be an event that is considered in the 9-week SARS-CoV-2 infection rate primary endpoint.Measure: cumulative incidence of SARS-CoV-2 infection Time: within 9 weeks from randomization
Description: Patients who are positive for SARS-CoV-2 (as defined above) who develop a new oxygen requirement attributable to COVID-19, tachypnea (RR > 20), or those who require hospitalization due to COVID-19 will be considered to have severe COVID-19.Measure: cumulative incidence of severe COVID-19 or death Time: within 12 weeks of randomization
Low doses of radiation in the form of chest X-rays have been used to treat people with pneumonia. This treatment was found to be effective by reducing inflammation and with minimal side effects. However, it was an expensive treatment and was eventually replaced with less costly treatments such as antibiotics. Radiation has also been shown in some animal experiments to reduce some types of inflammation. Some patients diagnosed with COVID-19 pneumonia will experience worsening disease, which can become very serious, requiring the use of a ventilator. This is caused by inflammation in the lung from the virus and the immune system. For this study, the x-ray given is called radiation therapy. Radiation therapy uses high-energy X-ray beams from a large machine to target the lungs and reduce inflammation. Usually, it is given at much higher doses to treat cancers. The purpose of this study is to find out if adding a single treatment of low-dose x-rays to the lungs might reduce the amount of inflammation in the lungs from a COVID-19 infection, which could help a patient to breathe without use of a ventilator.
Description: Death date of subjects will be collected from the date of radiation up to 1 month post radiation doseMeasure: Mortality rate of subjects treated with whole lung low-dose radiation Time: up to 28 days post radiation delivery
Description: Subject survival will be collected in number of days through 18 months post treatmentMeasure: Survival rate of subjects treated with whole lung low-dose radiation Time: up to 18 months post radiation delivery
Description: Number of intensive care daysMeasure: Change in number of Intensive care unit days Time: up to 28 days post radiation delivery
Description: Number of days using supplemental oxygenMeasure: Change in number of days using supplemental oxygen Time: up to 28 days post radiation delivery
Description: Oxygenation index/oxygen saturation until extubationMeasure: Change in oxygenation index/oxygen saturation index for 14 days post treatment or until extubated Time: up to 28 days post radiation
Description: Measure as a percent, the amount of pneumonia involvement of each lung segment (right upper lobe, right middle lobe, right lower lobe, left upper lobe and left lower lobe) from chest CT images at day 7, 14 and 28. Each lung segment can have involvement from 0 % (no involvement) up to 100% (complete pneumonia involvement of segment)Measure: Quantitation of Lung Involvement using Chest CT Time: up to 28 days post radiation
Description: Semi-quantitation of ground glass opacities or lung opacification with a score of 0-5 from Chest CT images at day 7, 14 and 28 for each of the 5 lobes of the lungs. The scoring system is as follows: 0, no involvement; 1, <5% involvement; 2, 25% involvement, 3, 26-49% involvement; 4, 50-75% involvement; and 5, >75% involvement.Measure: Quantitation of Lung Opacities using Chest CT Time: up to 28 days post radiation
Description: Determine viral titers at baseline, days 7, 14 and 28.Measure: SARS-CoV2 viral titers Time: up to 28 days
Description: Review adverse events, including severity and duration, for all subjects to determine safety of the radiation treatment for pneumonia due to COVID-19.Measure: Incidence of adverse events, including severity and duration, for administration of low dose radiation to lungs Time: up to 28 days
Description: Performance status will be evaluated using the Karnofsky Performance Scale Index at baseline, 7, 14 and 28 days post radiation dose. Scores range from 100 (normal, no complaints) to 0 (dead). A higher number indicates the ability to carry out normal daily activities.Measure: Change in performance status after low dose radiation to lungs Time: up to 28 days
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports